Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Ridaforolimus (Primary) ; Carboplatin; Paclitaxel
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Salivary gland cancer; Sarcoma; Solid tumours; Urethral cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 13 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History